Abstract
8555 Background: L19IL2 is a tumor targeted immunocytokine constituted by a single chain Fragment variable (scFv) format directed against the extradomain-B of fibronectin and the human cytokine interleukin-2 (IL2). The recommended dose for monotherapy of advanced solid cancer patients was established to be 22.5 Mio IU L19IL2 on days 1, 3, and 5 of a 21-day cycle in a previous dose escalation study. Methods: Chemotherapy-naive patients with advanced melanoma and normal LDH were treated with L19IL2 as an i.v. infusion at a dosage of 22.5 Mio IU L19IL2 on days 1, 3 and 5 every 21 days in combination with DTIC 1,000 mg/m2 on day 1 for up to 6 treatment cycles. In the subsequent maintenance phase 22.5 Mio IU L19IL2 was applied biweekly, while DTIC was omitted. Tumor assessment was performed every 6 weeks. Data on safety and efficacy were evaluated using CTC v3.0 and RECIST criteria, respectively. Results: 22 patients were evaluable. Median age was 54.5 years (20-83). Treatment was well tolerated. There were no treatment related deaths; details of CTC evaluation will be presented. Median number of applied induction cycles was 6 (range 2-6), 6/22 patients entered the maintenance phase. Several RECIST-confirmed tumor responses and durable disease stabilizations were observed. Updated efficacy data will be available for presentation. Conclusions: L19IL2 at a dose of 22.5 Mio IU L19IL2 on days 1, 3, and 5 of a 3-weekly schedule can be safely combined with standard DTIC in metastatic melanoma patients. Toxicity was manageable and reversible. Preliminary evaluation suggests clinical activity of the L19IL2/DTIC regimen in metastatic melanoma patients. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Philogen Philogen, Bayer Philogen
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.